Vendor Intelligence Report: Precision Peptide Co

Published 13 Jun 2026. 24-page investigative report on who is behind Precision Peptide Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 21 Finnrick lab tests, Precision Peptide Co passed 15 and failed 6, for an overall pass rate of 71%. The catalog split is plain: GHK-Cu and Ipamorelin are the cleaner reads, while Semaglutide and BPC-157 drive the caution. Ratings are also methodology-sensitive under stricter purity/fill grading, so the headline average is only a starting point.

The strongest safety signal is a same-batch Semaglutide pair: one vial near claim, one severe overfill. That finding does not condemn every Precision product, but it does weaken batch identity for this vendor’s GLP-1 stock. The archived COA trail adds a verification gap because batch numbers appear without a named lab, accreditation, or analyst.

The business record is short and uneven. The domain dates to late 2023, the 2024 archived storefront marketed USA-lab testing, and the official domain later failed DNS resolution. Registry work found similar-name Texas LLCs that did not match the vendor; a Forney Precision Shop footprint was marked permanently closed; ownership rests on a public Brandon Hoffman post rather than a clean corporate filing.

Trust signals deteriorate in the same window: a removed Trustpilot profile, low secondary trust score, late-stage fulfillment complaints, and reports of Bitcoin-only payment before shutdown. The buyer guidance is directional, not blanket: legacy Precision stock needs peptide-specific lab context and hard provenance checks.

Inside the full report:

  • Appendix A with per-product pass/fail rates, methodology-divergence charts, and rating trajectories for all five tested products
  • SEM5-0002 Semaglutide certificate evidence comparing the same-batch vial anomaly
  • Wayback/CDX timeline and archived Why Precision Peptides testing-claim exhibits
  • Texas Comptroller lookalike-entity analysis and Forney Precision Shop footprint exhibits
  • Ownership/personnel analysis covering Brandon Hoffman, Damien, Jesse, and Reform Research open leads
  • Trustpilot removal, shutdown/payment history, and affiliate/coupon disclosure review

Risk assessment

  • Semaglutide dosing-inconsistency risk — high: SEM5-0002 same-batch vials tested at 5.68mg and 32.9mg; one vial was +487.5% over the 5.6mg claim.
  • Unannounced shutdown and no-recourse payment risk — high: Official site was offline/DNS-failing by the field run, no customer notice surfaced, and reports describe a Bitcoin-only payment shift before shutdown.
  • Trust-profile integrity risk — high: Trustpilot removed Precision Peptide Co's profile for guideline violations, invalidating the prior review signal.
  • BPC-157 product-quality risk — medium: BPC-157 shows a 49.8% Finnrick rating across 5 tests (3 pass / 2 fail), materially weaker than GHK-Cu and Ipamorelin.
  • COA-verification risk — medium: Vendor testing claims and COAs did not name the lab, accreditation, or analyst; this affects all products.
  • Ownership and legal-entity opacity risk — medium: No matching operating entity was identified; ownership relies on a public Brandon Hoffman social-media statement.
  • Affiliate-promotion disclosure risk — medium: One Reddit discount code and coupon-site links/codes surfaced without clear disclosure; scale appears limited but transparency is weak.